Skip to main content

Phase 1 vs. Phase 2 Deal Valuation Comparison

Phase 1 Median Upfront
$90M
Total: $882M
Phase 2 Median Upfront
$258M
Total: $1.6B
Phase Transition Premium
86%
Phase 2 premium over Phase 1
Phase 1 Royalty Range
8.6%-15%
vs Phase 2: 11.8%-19.3%
Model Your Deal

Market Analysis

The Phase 1 to Phase 2 transition represents the most significant value inflection point in pharmaceutical licensing. Phase 2 small molecule deals carry a median total deal value of $1.6B compared to $882M at Phase 1, representing a 86% premium for clinical proof-of-concept data. Upfront payments increase from $90M to $258M.

The risk-adjusted deal structures differ significantly between phases. Phase 1 deals are heavily milestone-weighted with $317M in development milestones, while Phase 2 deals shift toward higher upfronts and commercial milestones. Phase 1 development milestones often include proof-of-concept triggers that Phase 2 deals have already de-risked. Regulatory milestones increase from $277M to $552M.

Royalty rates also reflect the de-risking premium. Phase 1 base royalties range from 8.6% to 15%, while Phase 2 assets command 11.8% to 19.3%. The optimal licensing window for most assets is immediately after Phase 2a proof-of-concept data, when the risk-value trade-off most favors the licensor.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical deal value premium from Phase 1 to Phase 2?
Phase 2 deals command a 86% premium over Phase 1 in total deal value ($1.6B vs $882M). The upfront payment increase is even more pronounced: $258M vs $90M, reflecting the de-risking value of proof-of-concept clinical data.
How do risk-adjusted deal terms differ between Phase 1 and Phase 2?
Phase 1 deals allocate a larger share to development milestones ($317M) relative to upfront payments, reflecting higher clinical risk. Phase 2 deals shift the value split toward upfront ($258M) and commercial milestones, reflecting the reduced probability of clinical failure after proof-of-concept data.
When is the optimal time to out-license a pharmaceutical asset?
The optimal licensing window depends on therapeutic area and modality, but the Phase 2a readout inflection point is generally the most favorable for licensors. At this stage, clinical proof-of-concept has been established, the asset carries a de-risking premium, and the licensee still captures substantial upside from Phase 3 and commercialization. Pre-Phase 2a licensing is appropriate when capital constraints or platform validation needs outweigh the value of additional de-risking.

Related Benchmarks

Preclinical Deal Benchmarks

View

Phase 2 Deal Benchmarks

View

Phase 3 Deal Benchmarks

View

Oncology Deal Overview 2026

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating